Marketing

Amarin decides to go it alone in Europe, as uncertainty clouds heart drug's US future

Chief executive John Thero said the company decided against "multiple proposals" for sales partnerships on Vascepa in Europe. Doing so, however, keeps the pressure on Amarin to deliver.

By Ben Fidler • Aug. 04, 2020

Biogen points to COVID-19 for disappointing drug launch

Sales of Vumerity, a key new product in Biogen's plan to bolster its multiple sclerosis drug business, have been slow since it launched in December.

By Jacob Bell • July 22, 2020

Ohio sues Express Scripts for overcharging state pension fund

"We want our money back," attorney general Dave Yost said, arguing Express Scripts "egregiously charged for services it didn't deliver." It's the latest action taken by the state against pharmacy benefit managers. 

By Samantha Liss • July 15, 2020

AbbVie's 'drip-feed' of patents shields top cancer drug from competition, group says

More than seven dozen patents have been granted for Imbruvica in the U.S., helping AbbVie create a legal defense that could protect the drug until 2036. 

By Kristin Jensen • July 15, 2020

Sponsored by Crossix

4 months with COVID-19: Impact on US health and media behaviors

To help pharmaceutical companies navigate the volatile industry landscape, Crossix has continued to monitor country-wide health and media behaviors.

Providers, insurers back ad campaign urging patients to stop 'medical distancing'

Since the pandemic's onset in the United States, health officials have been concerned about the consequences of routine and preventive care being delayed or put off entirely. Providers also fear further revenue loss.

By Shannon Muchmore • July 08, 2020

Novartis to pay $678M to settle claims over 'sham' doctor events

The Swiss drugmaker admitted to hosting lavish dinners and events that were intended to convince doctors to prescribe Novartis heart and diabetes drugs.

By Ned Pagliarulo • July 02, 2020

Gilead pricing suggests it will make a business out of COVID-19 drug

Even at the lower end of its price range, remdesivir could earn Gilead a billion dollars. How well the drug's price is received will be an important test for other companies working on coronavirus treatments.

By Jacob Bell • June 30, 2020

Gilead sets price for COVID-19 drug remdesivir

A typical course of treatment with remdesivir will cost between $2,340 and $3,120 in the U.S., a price range that likely ensures Gilead earns a profit on sales of the drug.

By Ned Pagliarulo • June 29, 2020

Sponsored by IQVIA

Promotional deployment during COVID-19: Quarantine and re-entry

The time is now to shift promotional efforts from live to virtual engagement channels.

Pandemic pushes FDA to 'accelerate' real-world evidence efforts, Hahn says

The agency has grappled with how to use real-world data in regulating drugs and medical devices, but is now leaning on it to update emergency use authorizations, FDA chief Stephen Hahn said.

By Maria Rachal • June 19, 2020

Sponsored by IQVIA

Medical Science Liaisons carry the day with key opinion leaders during the COVID-19 pandemic

Now, more than ever, it's worth investing in Medical Science Liaisons.

By Tonya Broyles and Dave (William) Dawson • June 19, 2020

In FDA 1st, game-based therapeutic gets marketing approval

Digital therapeutics developer Akili won authorization from the agency for a treatment meant to improve attention in children with ADHD.

By Maria Rachal • June 16, 2020

Pressure on generic drugmakers increases with new price fixing lawsuit

The case claims that companies, including Pfizer, Mylan and Novartis, divided the market up into a "fair share" arrangement that allowed them all to raise prices without fearing competition.

By Jonathan Gardner • June 10, 2020

Ex-FDA official slams 'chaos' caused by agency's hands-off approach to antibody tests

Jesse Goodman said the agency's decision to allow developers to self-validate COVID-19 blood assays led to widespread marketing of low-quality tests.

By Nick Paul Taylor • June 10, 2020

Sponsored by IQVIA

Access teams deserve a fresh look during the COVID-19 pandemic

Now, more than ever, it's a good time to rethink your access-staffing model.

By Lisa Blanton, Senior Director, Offering Development, Contract Sales and Medical Solutions, IQVIA • June 08, 2020

Novartis multiple sclerosis drug review delayed by FDA

The Swiss drugmaker now expects a decision on approval by September of ofatumumab, an important drug in its plans to compete with rival Roche. 

By Kristin Jensen • June 03, 2020

CVS sued by Blue Cross plans alleging they were overcharged on generic drugs

BCBS plans in six states contend CVS Health concealed true cash prices for more than a decade. The plans seek to recoup millions of dollars.

By Samantha Liss • May 28, 2020

Medicare telehealth use surged as regulations eased in early weeks of pandemic

CMS is weighing whether to extend telehealth waivers past the scope of the COVID-19 national emergency, agency head Seema Verma has said.

By Rebecca Pifer • May 27, 2020

Trump administration touts plan to limit insulin costs for seniors

Drugmakers Eli Lilly, Novo Nordisk and Sanofi will participate in the voluntary program, which the president rolled out Tuesday in a Rose Garden address.

By Rebecca Pifer • May 26, 2020

Sponsored by IQVIA

Patient engagement in the time of COVID-19

Now, more than ever, it's important to reach patients with information, encouragement, and support.

By Robyn Stoy, Director, Patient Engagement, Contract Sales and Medical Solutions, IQVIA • May 25, 2020

Hospitals, device industry set ground rules for sales reps' return

The guidance expands on advice for resuming elective surgery that a group of medical societies and the American Hospital Association released in April.

By Susan Kelly • May 20, 2020

Hospitals balk as CMS doubles down on price transparency

The draft rule released by CMS Monday would also create a new billing code for CAR-T cancer therapies, which hospitals often lose money on. 

By Shannon Muchmore • May 12, 2020

Pharmas boosted by drug stockpiling, but warn of COVID-19 impact

Patients and wholesalers stocked up on medicines early in 2020, lifting first-quarter sales for many pharmas. But that boost is likely fleeting, disguising the substantial effects the pandemic is having on their businesses.

By Ned Pagliarulo • April 28, 2020

Launch for Neurocrine Parkinson's drug put on hold because of coronavirus

CEO Kevin Gorman told BioPharma Dive it's an inappropriate time to be pitching the drug to neurology doctors, many of who are devoting time to hospitals grappling with COVID-19 cases.

By Jacob Bell • UPDATED: April 27, 2020 at 10:44 a.m.